Nucl Med Mol Imaging.  2025 Feb;59(1):41-49. 10.1007/s13139-024-00899-6.

¹⁸F-FDOPA PET/CT in Oncology: Procedural Guideline by the Korean Society of Nuclear Medicine

• Park YJ
• Choi JH
• Lee H
• Moon SH
• Lee I
• Lee J
• Yoo J
• Choi JY
• The Korean Society of Nuclear Medicine Medical Affairs Committee

• KMID: 2565521
• DOI: http://doi.org/10.1007/s13139-024-00899-6

Abstract

This guideline outlines the use of 3,4-dihydroxy-6- ¹⁸F-fluoro-L-phenylalanine positron emission tomography / computed tomography for the diagnosis and management of neuroendocrine tumors, brain tumors, and other tumorous conditions. It provides detailed recommendations on patient preparation, imaging procedures, and result interpretation. Based on inter-national standards and adapted to local clinical practices, the guideline emphasizes safety, quality control, and the effec-tive application of 3,4-dihydroxy-6- ¹⁸F-fluoro-L-phenylalanine positron emission tomography / computed tomography for various tumors such as insulinomas, pheochromocytomas, and medullary thyroid carcinoma. It also addresses the use of premedication with carbidopa, fasting protocols, and optimal imaging techniques. The aim is to assist nuclear medicine professionals in delivering precise diagnoses, improving patient outcomes, and accommodating evolving medical knowl-edge and technology. This comprehensive document serves as a practical resource to enhance the accuracy, quality, and safety of 3,4-dihydroxy-6- ¹⁸F-fluoro-L-phenylalanine positron emission tomography / computed tomography in oncology.

Keyword

FDOPA PET/CT; Oncology ; Guideline